Name | Description |
---|---|
BreastER | Node-negative breast carcinomas, P = 3398 (3,398 cDNA clones) [19] 23 Estrogen receptor α positive (ER+) 24 Estrogen receptor α negative (ER-) |
BreastBRCA | Primary breast tumors, P = 3226 (6,512 cDNA clones) [20] 7 BRCA1 mutation (BRCA1) 8 BRCA2 mutation (BRCA2) 7 Sporadic (Sporadic) |
OvarianBRCA | Primary epithelial ovarian adenocarcinomas; P = 6445 (7,651 cDNA clones) [21] 18 BRCA1 mutation (BRCA1) 16 BRCA2 mutation (BRCA2) 27 Sporadic (Sporadic) http://jncicancerspectrum.oupjournals.org/cgi/content/full/jnci;94/13/990/DC1 |
LungStanford | Lung tumors; P = 918 (blanks set to average, 24,000 cDNA clones) [22] 41 Adenocarcinomas (AC) 16 Squamous cell carcinomas (SCC) |
LungBeer | Lung tissue samples; P = 4966 (4,966 cDNA clones) [23] 10 Non-neoplastic (Normal) 86 Adenocarcinomas (AC) http://www.nature.com/nm/journal/v8/n8/suppinfo/nm733-S1.html |
Cutaneous | Cutaneous melanomas; P = 3613 (the "detected" set, 8,150 cDNA clones) [24] 31 Melanoma biopsies (Melanoma) 7 Tumor cell lines (Cell line) http://research.nhgri.nih.gov/microarray/Melanoma_Supplement |
GIST | Tumors; P = 1987 (1,987 cDNA clones) [25] 13 KIT-mutation positive gastrointestinal stromal tumors (KIT+) 6 Spindle cell tumors from locations outside gastrointestinal tract (Spindle) |
YeohALL | Pediatric, acute lymphoblastic leukemia bone marrows; P = 4196 (10000 variation filter, 12,625 Affymetrix HG_U95Av2 probes) [26] 43 T-lineage ALL (T) 27 E2A-PBX1 (E2A) 15 BCR-ABL (BCR) 79 TEL-AML1 (TEL) 20 MLL (MLL) 64 Hyperdiploid>50 (Hyperdip50) |
Prostate | Prostate tissue samples; P = 3958 (12,626 Affymetrix U95a probes) [27] 25 Primary cancer tissue (Tumor) 9 Non-neoplastic tissue (Normal) |
Liver | Liver Cancer (Hepatocellular carcinoma); P = 6605 (cDNA clones) [1] 105 Tumor (Tumor) 76 Normal (Normal) |